Keyphrases
Placebo-controlled Study
100%
Schizophrenic Patients
100%
Cognitive Dysfunction
100%
Chronic Schizophrenia
100%
Mianserin
100%
5-HT2
100%
Wisconsin Card Sorting Test
40%
Antagonism
40%
Cognitive Effects
40%
Serotonin 2A Receptor (5-HT2AR)
40%
Typical Antipsychotics
40%
Automated Neuropsychological Assessment Metrics
40%
Schizophrenia
20%
Clinical Ratings
20%
Performance Improvement
20%
Cognitive Deficits
20%
Executive Function
20%
DSM-IV
20%
Rating Scales
20%
Clinical Assessment
20%
Between-group Difference
20%
Cognitive Functioning
20%
Learning Memory
20%
Placebo Groups
20%
Sustained Attention
20%
Memory-guided Attention
20%
Memory-based Learning
20%
Learning Attention
20%
Neurocognitive Testing
20%
Serotonin
20%
Flexible Dose
20%
Atypical Antipsychotics
20%
5-HT2A Antagonist
20%
5-HT System
20%
Dopamine D2
20%
Learning Tests
20%
Neuroscience
Cognitive Disorders
100%
Placebo
100%
5-HT2 Antagonists
100%
Mianserin
100%
Wisconsin Card Sorting Test
40%
Typical Antipsychotic
40%
Neuropsychological Assessment
40%
Clinical Assessment
20%
Serotonin
20%
Atypical Antipsychotic
20%
5-HT2A Antagonists
20%
Executive Function
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cognitive Defect
100%
Placebo-Controlled Study
100%
Mianserin
100%
Serotonin 2 Antagonist
100%
Typical Antipsychotic
40%
Placebo
20%
DSM-IV
20%
Serotonin
20%
Atypical Antipsychotics
20%
Serotonin 2A Antagonist
20%